scott gottlieb next.tions and experiences for hundreds of thousands of fans with reliable 5g connectivity. now's the time to accelerate your business. power e*trade's award-winning trading app makes trading easier. with its customizable options chain, easy-to-use tools and paper trading to help sharpen your skills, you can stay on top of the market from wherever you are. e*trade from morgan stanley. power e*trade's easy-to-use tools make complex trading less complicated. custom scans help you find new trading opportunities, while an earnings tool helps you plan your trades and stay on top of the market. e*trade from morgan stanley. use the all new stock screener to unlock new investment ideas using your criteria, you the power goes out and we still have wifi to do our homework. and that's a good thing? great in my book! who are you? no power? no problem. introducing storm-ready wifi. now you can stay reliably connected through power outages with unlimited cellular data and up to 4 hours of battery back-up

scott gottlieb. he also serves on the boards of pfizer. at has got to be part of it. >> absolutely and the drugs they are developing to support the continued use of these drugs showing public health gains in terms of reductions in cardiovascular death by stroke or heart attack . we will see competition heat up, first is on price, we did an analysis and found in the market price the net prices received is 48% 70% lower than the list price is on these drugs. the net price paid to the manufacturers is close to $290 and the discounts in the market place, the list price is around $1300, that is before the competition entered the market from eli lilly. i think we will see more discounting and these net prices will come down. we will also see competitions on the label . if you look at novo they have put out studies showing cardiovascular benefits of these drugs, those benefits were going to get into the label, they will get those in the drug label through the fda. the fda will not extend the benefits that novo was able to demonstrate onto eli lill

scott gottlieb, a guest earlier on "squawk box," very informative. >> on the board of lumina and pfizeryers. this is key to whether you get health insurers. lilly shares were down yesterday. >> the worst day of the year for ibb. >> it was down 4.6%, and one of the reasons why is that people say, look, astrazeneca is working on a pill form no kidding that's ridiculous. i thought that the eli lilly interview that morgan did was dispositive about why you wanted to be in eli lilly i know that novo is building a $5 billion plant, but there's room for everyone. this is not unlike the great cholesterol moment where you had merck leading and then out of nowhere, warner lambert came out of nowhere >> lipitor, there's been a generic for many years >> i like regeneron. i like the amgen drug for cholesterol, repatha, which is remarkable, which we realize any close cholesterol is probably bad for you. >> we're waiting on the sea gen deal you scared a lot of people in pfizer last friday night, what'd you say on "mad money" >> what? i just said -- >> did you say something about the deal >> i like sea

scott gottlieb. i asked. it makes sense. you lose weight and your heart has less cardiac events. the point is it may not be related to that at all. so you don't know why? your heart works better, but your kidneys stop working. we don't know. that's not true. if you don't know the mechanism for why something is happening, are their side effects? positive effects are great. do we not know about side effects? this is not the first time. we talked about the story with pulmonary hypertension. they were taking this compound called silvenafil. whoa, what is that? that turned into hviagra. it turned into the best selling drug. monoxodil for hair? there are other times -- i don't think. >> you are right to worry about the unintended side effects. this could have more miracle effects. >> i want to know -- >> the mechanism. >> what is the beneficial to the heart? it is diabetes. all of these were for diabetes and weight loss. it would be good to know what is causing it. the vaccines and we hear and see it. >> i go back to fen-phen. it is great news if it is stopping other things from happen

scott gottlieb, former fda commissioner and cnbc contributor who is also on the boards of alumina andown 44, 45, 46% as we were watching it yesterday. the gene therapy has already been approved, but did not meet the end points. what did you think when you heard that news? >> the product received accelerated approval in june for 4 and 5-year-olds based on data showing it could improve the production of the missing protein in duchenne muscular disd dyst dystrophy. this was done to confirm the clinical benefits, done to demonstrate the drug at the gene therapy actually improves function in those children. they missed the primary end point on a scale of 17-point scale of things like to step on and off a box or rise from a chair. it reached significance on secondary end points like the ability to walk ten meters or the ability to rise off the floor. so the data was mixed. there was some oddities about the trial. the placebo arm showed significant improvement as well as the active arm, the active arm showed more improvement than the placebo arm, but you saw improvement in the children who w